logo-loader
Instem PLC

Instem secures US$750,000 contract with Fortune 500 heavyweight

Phil Reason, chief executive of Instem Plc (LON:INS), tells Proactive Investors a Fortune 500 medical products and pharma company has adopted its Samarind Regulatory Management System.

The deal is worth an initial US$750,000, with 80% of that sum being recognised this year, and brings with it recurring annual revenues of US$169,000.

Quick facts: Instem PLC

Price: £3.65

Market: AIM
Market Cap: £59.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Instem seeing all clients place orders as healthcare market stays buoyant

Phil Reason, chief executive of healthcare AI software group Instem PLC (LON:INS), says business was strong across all areas of the group in the first six months of 2019. Even a change from licences to a SaaS or pay-as you-use model has gone smoothly, he says, with cash inflows strong...

4 weeks ago

2 min read